

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



山東威高集團醫用高分子製品股份有限公司

Shandong Weigao Group Medical Polymer Company Limited *

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1066)

TERMINATION OF MAJOR AND DISCLOSEABLE TRANSACTIONS

Reference is made to the announcements of the Company dated 15 June 2016, 6 July 2016, 28 July 2016, 18 August 2016, 29 September 2016, 20 October 2016, 3 November 2016 and 29 November 2016 (collectively, the “**Announcements**”). Unless otherwise stated, capitalized terms used herein shall have the same meaning as those defined in the Announcements.

As a result of the uncertainty on the regulatory policy related to the Proposed Transaction in the PRC, the parties to the Proposed Transaction have decided not to proceed with the Proposed Transaction. On 30 March 2017, (i) the Company and Weigao Logistic, among others, entered into the termination agreement to terminate the Asset Transfer Agreement; (ii) the Company and Winbase International entered into the termination agreement to terminate the Compensation Agreement; (iii) the Company and Shiyou Chemical entered into the termination agreement to terminate the Share Transfer Agreement; (iv) Winbase International and the Company entered into the termination agreement to terminate the Subscription Agreement; and (v) Winbase International and the Placees entered into termination agreements in respect of the Placing Agreements, with immediate effect. The rights and obligations of the parties to each of the Asset Transfer Agreement, the Compensation Agreement, the Share Transfer Agreement, the Subscription Agreement and the Placing Agreements have ceased upon termination.

* *For identification purpose only*

The Board considers that the termination of each of the Asset Transfer Agreement, the Compensation Agreement, the Share Transfer Agreement, the Subscription Agreement and the Placing Agreements is in the interest of the Company and its Shareholders as a whole and has no material adverse impact on the existing business or financial position of the Group.

By Order of the Board
Shandong Weigao Group Medical Polymer Company Limited
Zhang Hua Wei
Chairman

30 March 2017

Weihai, Shandong Province, the PRC

As at the date of this announcement, the Board Comprises:

Mr. Zhang Hua Wei (*Executive Director*)

Mr. Wang Yi (*Executive Director*)

Mr. Gong Jian Bo (*Executive Director*)

Mr. Xia Lie Bo (*Executive Director*)

Mrs. Zhou Shu Hua (*Non-executive Director*)

Mr. Lo Wai Hung (*Independent non-executive Director*)

Mrs. Fu Ming Zhong (*Independent non-executive Director*)

Mrs. Wang Jin Xia (*Independent non-executive Director*)